- Home
- LUNG vs OBIO Comparison
LUNG vs OBIO Comparison
Compare LUNG & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- OBIO
- Stock Information
- Founded
- LUNG 1995
- OBIO 2017
- Country
- LUNG United States
- OBIO United States
- Employees
- LUNG N/A
- OBIO N/A
- Industry
- LUNG Industrial Specialties
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- LUNG Health Care
- OBIO Health Care
- Exchange
- LUNG Nasdaq
- OBIO Nasdaq
- Market Cap
- LUNG 106.3M
- OBIO 118.8M
- IPO Year
- LUNG 2020
- OBIO N/A
- Fundamental
- Price
- LUNG $3.09
- OBIO $3.16
- Analyst Decision
- LUNG Buy
- OBIO Strong Buy
- Analyst Count
- LUNG 6
- OBIO 5
- Target Price
- LUNG $11.53
- OBIO $14.20
- AVG Volume (30 Days)
- LUNG 408.2K
- OBIO 137.0K
- Earning Date
- LUNG 07-30-2025
- OBIO 08-11-2025
- Dividend Yield
- LUNG N/A
- OBIO N/A
- EPS Growth
- LUNG N/A
- OBIO N/A
- EPS
- LUNG N/A
- OBIO N/A
- Revenue
- LUNG $87,473,000.00
- OBIO $2,886,000.00
- Revenue This Year
- LUNG $18.02
- OBIO $20.47
- Revenue Next Year
- LUNG $18.17
- OBIO $11.45
- P/E Ratio
- LUNG N/A
- OBIO N/A
- Revenue Growth
- LUNG 19.84
- OBIO 30.23
- 52 Week Low
- LUNG $2.50
- OBIO $2.37
- 52 Week High
- LUNG $9.37
- OBIO $7.68
- Technical
- Relative Strength Index (RSI)
- LUNG 50.76
- OBIO 52.36
- Support Level
- LUNG $3.03
- OBIO $3.05
- Resistance Level
- LUNG $3.88
- OBIO $3.24
- Average True Range (ATR)
- LUNG 0.34
- OBIO 0.17
- MACD
- LUNG 0.05
- OBIO 0.03
- Stochastic Oscillator
- LUNG 39.23
- OBIO 42.19
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.